SAMe - NutraPedia

Back to Table of Contents

Research Overview

Across the studies reviewed here, research on S-adenosyl-L-methionine (SAM-e) is most developed in two clinical domains: major depressive disorder (MDD) and musculoskeletal pain/osteoarthritis. In psychiatry, SAM-e is discussed within evidence-based guideline frameworks (e.g., CANMAT 2016) and in clinical trial reviews/meta-analytic contexts, primarily as an oral natural health product evaluated for antidepressant effects. In osteoarthritis, SAM-e appears in clinical overviews as one of several nonpharmacologic or supplement options that “may offer some benefit,” suggesting it has been studied but is not positioned as a core, high-certainty therapy compared with exercise, weight loss, NSAIDs, and intra-articular corticosteroids. Other mentions in the studies (e.g., boron influencing SAM-e biochemistry; “SAM” as self-assembled monolayers; “SAM-E” as a bacteriophage name) are not clinical SAM-e efficacy research and do not directly inform therapeutic conclusions about SAM-e supplementation.

The strongest support in these studies is for SAM-e in mild-to-moderate MDD, where guideline-level synthesis (CANMAT 2016) places SAM-e among first- or second-line complementary/alternative options based on available efficacy and tolerability data, and an earlier clinical evidence review reports that oral SAM-e monotherapy reduced depressive scores in 4 of 5 small randomized controlled trials. This indicates a signal of antidepressant efficacy, albeit derived largely from small studies and summarized within broader CAM evidence appraisals rather than large, definitive contemporary trials. For knee osteoarthritis, the evidence presented is weaker and more qualified: SAM-e is listed among interventions that may help, without strong comparative or high-certainty endorsement, implying modest or inconsistent benefit relative to established first-line conservative measures.

Key gaps highlighted or implied by these studies include the need for larger, well-designed randomized trials (with adequate power, standardized dosing, and longer follow-up) to clarify SAM-e’s effect size, durability of benefit, and patient subgroups most likely to respond—particularly in depression where existing trials are described as small and guidelines note methodological limitations and limited long-term outcome data. Additional research is also needed on safety in real-world use, including drug–supplement interactions (explicitly flagged in the CANMAT guideline caveats), and on comparative effectiveness versus standard treatments and as adjunctive therapy (not only monotherapy). For osteoarthritis, more rigorous trials would be required to determine clinically meaningful pain/function improvements, optimal dosing, and how SAM-e compares with or complements established nonpharmacologic and pharmacologic strategies.

1. What conditions has SAM-e been studied for?

  • Major depressive disorder (MDD): Evaluated as a “natural health product”/complementary intervention in adults with MDD, including as monotherapy in randomized controlled trials and discussed in clinical guidelines.

  • Knee osteoarthritis (OA): Mentioned among non-opioid options that “may offer some benefit” for knee OA symptom management.

  • Pharmacokinetics/safety of an oral formulation: A Phase 1 study of a high-bioavailability enteric-coated SAM-e tablet (MSI-195) assessed safety, dose proportionality, and pharmacokinetics (not an efficacy study).

  • Not relevant to SAM-e the supplement (term overlap): Several studies use “SAM” to mean self-assembled monolayers or “SAM-E.f 12” as a bacteriophage name; these are unrelated to S-adenosyl-L-methionine supplementation.

2. Does it work in treating those conditions? Summarize the evidence.

  • MDD (depression): suggestive evidence of benefit, strongest for mild-to-moderate and short-term use; limitations noted.

    • A review of CAM trials reports that oral SAM-e monotherapy reduced depressive scores in 4 of 5 small randomized controlled trials, concluding it is “promising” but that further study is warranted.

    • A separate critical review of placebo-controlled studies found 8 of 14 (57%) SAM-e studies in MDD were positive, but emphasized that most were methodologically flawed and that more rigorous data are needed before drawing definitive conclusions.

    • The 2016 CANMAT guidelines (CAM section) list SAM-e as a first- or second-line option for mild-to-moderate MDD, while also highlighting methodological limitations and a paucity of long-term outcomes and drug-interaction data.

  • Knee osteoarthritis: possible symptomatic benefit, but evidence strength is not established in these studies.

    • A knee OA clinical review states that SAM-e “may offer some benefit” (alongside acetaminophen, glucosamine, ginger, capsaicin, topical NSAIDs, acupuncture, tai chi). The study does not provide trial counts, effect sizes, or certainty ratings.

  • Formulation/PK (MSI-195): efficacy not addressed.

    • The Phase 1 abstract focuses on single-dose safety, dose proportionality (400/800/1600 mg), and pharmacokinetics versus a commercial product; it does not evaluate clinical outcomes.

3. What health benefits does it have?

  • Depressive symptom reduction (primary supported benefit in these studies)

    • Multiple reviews and the CANMAT guideline section collectively describe SAM-e as having antidepressant efficacy signals, particularly in mild-to-moderate MDD and generally in the short term.

  • Potential symptom relief in knee osteoarthritis

    • Included among agents that may reduce pain and/or improve function in knee OA, though the study does not quantify benefit.

  • General tolerability as a CAM option

    • The CANMAT CAM section notes CAM treatments are generally well tolerated (while also cautioning about limited long-term and interaction data).

4. Does it have any downsides or side effects?

  • Evidence limitations and uncertainty about long-term safety

    • CANMAT highlights methodological limitations in the evidence base and a paucity of long-term outcomes for CAM treatments including SAM-e.

    • The critical review concludes SAM-e data are “strongly suggestive” but not definitive due to methodological flaws in many studies.

  • Drug interactions: insufficient data

    • CANMAT explicitly notes limited data on drug interactions for CAM treatments (including SAM-e), which is a practical downside when combining with antidepressants or other medications.

  • Treatment-emergent suicidality: no signal detected in reviewed trials, but trials were not designed to detect it

    • The suicidality-focused review found no evidence of treatment-emergent suicidality for SAM-e in the reviewed placebo-controlled psychiatric studies, but emphasized that studies were not prospectively designed to reliably assess rare behavioral adverse events.

  • General side-effect details are not provided in these studies

    • None of the studies reviewed here enumerate specific common adverse effects (e.g., GI upset, insomnia) or quantify discontinuation rates for SAM-e; the Phase 1 study is described as assessing safety, but the study excerpt does not report outcomes.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • No pharmacogenomic findings are provided in these studies. None of the included summaries report differential SAM-e efficacy or adverse effects by genotype (e.g., methylation-cycle genes) or any validated gene–supplement interaction.

  • Evidence gap: Based on the studies reviewed here, there is insufficient evidence to claim SAM-e is beneficial or harmful for specific genetic variants. Any pharmacogenomic recommendations would require studies explicitly designed to test genotype-stratified outcomes.

Аdеmethionine in the treatment of fatigue in liver diseases: a systematic review

Ademethionine, regardless of the route of administration, is effective in the treatment of fatigue due to different liver disease in the short and long term.

Gender Related Changes in Gene Expression Induced by Valproic Acid in A Mouse Model of Autism and the Correction by S-adenosyl Methionine. Does It Explain the Gender Differences in Autistic Like Behavior?

In previous studies we produced autism like behavioral changes in mice by Valproic acid (VPA) with significant differences between genders. S-adenosine methionine (SAM) prevented the autism like behavior in both genders. SAM normalized the expression of most changed genes in both genders. We presume that genes that are involved in autism like behavior in our model were similarly changed in both genders and corrected by SAM.

[Meta-analysis of ursodeoxycholic acid and S-adenosylmethionine for improving the outcomes of intrahepatic cholestasis of pregnancy]

UDCA-SAMe combination therapy is better than either UDCA or SAMe monotherapy for improving the outcome of intrahepatic cholestasis of pregnancy without adverse effects.

S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research

S-adenosylmethionine holds promise as a treatment for multiple neuropsychiatric conditions, but the body of evidence has limitations. The encouraging findings support further study of SAMe in both psychiatric and comorbid medical illnesses.

Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysis

UDCA decreased the pruritus score, TBA, and ALT levels more effectively than SAMe, reducing the rate of preterm delivery for Intrahepatic Cholestasis of Pregnancy.

S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis

Furthermore, the results regarding ursodeoxycholic acid (UDCA) and stronger neo-minophagen C (SNMC) indicated that both treatments were more effective than SAMe was in certain chronic liver diseases. These findings suggest that SAMe could be used as the basis of a medication regimen for liver function improvement because of its safety. However, SAMe also demonstrated limited clinical value in the treatment of certain chronic liver diseases.

Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review

Data from both randomized and non-randomized studies suggest that AdoMet improves some biochemical liver parameters and symptoms of cholestasis within 2 wk, with further improvements observed in some studies after 4 and 8 wk of treatment.

S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review

The existing trials of SAMe, used as monotherapy or add on to another antidepressants, have shown encouraging and generally positive results.

Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study

Supplementation of SAMe and L. plantarum HEAL9 in adults with subthreshold or mild-to-moderate symptoms of depression resulted in fast and clinically relevant effects after 2 weeks. The combination was safe and significantly improved symptoms of depression, anxiety, and cognitive and somatic components. The effect of this novel product is independent from the severity of the symptoms unlike traditional antidepressants available on the market that have minimal benefits for subthreshold or mild-to-moderate symptoms.

Dietary supplementation with S-adenosyl methionine delays the onset of motor neuron pathology in a murine model of amyotrophic lateral sclerosis

Mutations in Cu/Zn superoxide dismutase 1 (SOD-1), associated with familial ALS, promote widespread oxidative damage. Dietary supplementation with S-adenosyl methionine (SAM) has provided multiple neuroprotective effects in mouse models of age-related cognitive pathology. SAM delayed disease onset by 2-3 weeks. SAM also delayed hallmarks of neurodegeneration in these mice and in ALS, including preventing loss of motor neurons, and reducing gliosis, SOD-1 aggregation, protein carbonylation, and induction of antioxidant activity.

S-adenosylmethionine mediates glutathione efficacy by increasing glutathione S-transferase activity: implications for S-adenosyl methionine as a neuroprotective dietary supplement

When maintained on a folate-deficient, iron-rich diet, transgenic mice lacking in apolipoprotein E (ApoE-/- mice) demonstrate impaired activity of glutathione S-transferase (GST), resulting in increased oxidative species within brain tissue despite abnormally high levels of glutathione. These mice also exhibit reduced levels of S-adenosyl methionine (SAM) and increased levels of its hydrolysis product S-adenosyl homocysteine, which inhibits SAM usage. Supplementation of the above diet with SAM restored GST activity and eliminated reactive oxygen species at the expense of stockpiled glutathione, suggesting that one or more SAM-dependent reactions were required to maintain GST activity. SAM also increased activity of purified rat liver GST and recombinant GST. These findings confirm that SAM can exert a direct effect on GST activity.

Heme oxygenase-1 is a novel target and antioxidant mediator of S-adenosylmethionine

Induction of the HO-1/ferritin-system leads to protection of tissues against several inflammatory stimuli. SAM increased the protein and mRNA levels of HO-1 in cultured endothelial cells. Induction of HO-1 gene expression was associated with elevated ferritin protein levels and regulated at the transcriptional level via increased promoter activity.

S-adenosyl methionine prevents endothelial dysfunction by inducing heme oxygenase-1 in vascular endothelial cells

Endothelial dysfunction is an early prerequisite for atherosclerosis. This study was undertaken to investigate the possible preventive effect of SAM on endothelial dysfunction and the molecular mechanism of its action. SAM treatment prevented endothelial dysfunction in high fat diet (HFD)-fed rats. In cultured human aortic endothelial cells, linoleic acid (LA) increased and SAM decreased cell apoptosis and endoplasmic reticulum stress. These data demonstrate that SAM treatment prevents endothelial dysfunction in HFDfed animals by inducing HO-1 in vascular endothelial cells.

S-Adenosylmethionine: a control switch that regulates liver function

Up to 85% of all methylation reactions and as much as 48% of methionine metabolism occur in the liver, which indicates the crucial importance of this organ in the regulation of blood methionine. Of the two mammalian genes (MAT1A, MAT2A) that encode methionine adenosyltransferase (MAT, the enzyme that makes AdoMet), MAT1A is specifically expressed in adult liver. It now appears that growth factors, cytokines, and hormones regulate liver MAT mRNA levels and enzyme activity and that AdoMet should not be viewed only as an intermediate metabolite in methionine catabolism, but also as an intracellular control switch that regulates essential hepatic functions such as regeneration, differentiation, and the sensitivity of this organ to injury. The aim of this review is to integrate these recent findings linking AdoMet with liver growth, differentiation, and injury into a comprehensive model. With the availability of AdoMet as a nutritional supplement and evidence of its beneficial role in various liver diseases, this review offers insight into its mechanism of action.

Down-regulation of rat liver beta-adrenergic receptors by cysteine

Down-regulation of hepatic beta-adrenergic receptors was indicated by a 56% decrease in the specific activity of 125I-iodocyanopindolol bound to rat liver membrane preparations from rats fed diets containing 15% of casein supplemented with cysteine, instead of methionine or unsupplemented. Down-regulation of hepatic beta-adrenergic receptors by cysteine appears to be mediated through an effect of cysteine on the tissue concentration of S-adenosyl methionine (SAM). The liver tissue concentration of SAM in rats fed cysteine-supplemented diets decreased 53% compared to those fed diets supplemented with methionine. The decrease in liver SAM in rats fed the diet supplemented with cysteine appears to reflect a non-competitive inhibition of methionine adenosyl-transferase by cysteine.

References

  1. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.
    Arun V Ravindran, Lynda G Balneaves, Guy Faulkner, Abigail Ortiz, Diane McIntosh, Rachel L Morehouse, Lakshmi Ravindran, Lakshmi N Yatham, Sidney H Kennedy, Raymond W Lam, Glenda M MacQueen, Roumen V Milev, Sagar V Parikh (2016) - Canadian journal of psychiatry. Revue canadienne de psychiatrie
  2. Nothing Boring About Boron.
    Lara Pizzorno (2015) - Integrative medicine (Encinitas, Calif.)
  3. Insights into the novel Enterococcus faecalis phage: A comprehensive genome analysis.
    Sahar Abed, Mohammad Sholeh, Mahshid Khazani Asforooshani, Morvarid Shafiei, Abdolrazagh Hashemi Shahraki, Shaghayegh Nasr (2024) - PloS one
  4. Complementary and alternative medicine for the treatment of major depressive disorder.
    Richard Nahas, Osmaan Sheikh (2011) - Canadian family physician Medecin de famille canadien
  5. Odd-even effect in the hydrophobicity of n-alkanethiolate self-assembled monolayers depends upon the roughness of the substrate and the orientation of the terminal moiety.
    Lucas B Newcomb, Ian D Tevis, Manza B J Atkinson, Symon M Gathiaka, Rafael E Luna, Martin Thuo (2014) - Langmuir : the ACS journal of surfaces and colloids
  6. St. John's wort and S-adenosyl methionine as "natural" alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit?
    David J Carpenter (2011) - Alternative medicine review : a journal of clinical therapeutic
  7. Spectroscopic evidence for the origin of odd-even effects in self-assembled monolayers and effects of substrate roughness.
    Jiahao Chen, Jian Liu, Ian D Tevis, Richard S Andino, Christina M Miller, Lawrence D Ziegler, Xin Chen, Martin M Thuo (2017) - Physical chemistry chemical physics : PCCP
  8. Pharmacokinetic study of a novel oral formulation of S-adenosylmethionine (MSI-195) in healthy subjects: dose escalation, food effect and comparison to a commercial nutritional supplement product.
    Beth R Cameron, Ludvina Ferreira, I David MacDonald (2020) - BMC pharmacology & toxicology
  9. Limits to the Effect of Substrate Roughness or Smoothness on the Odd-Even Effect in Wetting Properties of n-Alkanethiolate Monolayers.
    Jiahao Chen, Zhengjia Wang, Stephanie Oyola-Reynoso, Symon M Gathiaka, Martin Thuo (2015) - Langmuir : the ACS journal of surfaces and colloids
  10. A Prospective Randomized Double-Blind Study Evaluating UP165 and
    Douglas S Kalman, Samantha Feldman, Rafeal Rivas Vazquez, Diane R Krieger (2015) - Foods (Basel, Switzerland)
  11. Dietary supplement drug therapies for depression.
    Robert H Howland (2012) - Journal of psychosocial nursing and mental health services
  12. Efficacy of adenosylmethionine combined with Si Mo Tang in treatment of neonatal jaundice.
    Ling Li, Jingqun Wang, Shuxia Geng, Fang Liu, Lili Ping, Xiaohong Gu, Xueai Fan, Mei Yang, Lixia Liang, Wei Guo (2022) - American journal of translational research
  13. A pilot study of S-adenosylmethionine in treatment of functional abdominal pain in children.
    Lillian J Choi, Jeannie S Huang (2013) - Alternative therapies in health and medicine

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Upload raw DNA data to get started with your free dna raw data analysis today!